Difference between revisions of "Ramucirumab (Cyramza)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
m |
||
| Line 23: | Line 23: | ||
==Also known as== | ==Also known as== | ||
| − | IMC-1121B | + | IMC-1121B, LY3009806 |
==References== | ==References== | ||
| Line 29: | Line 29: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| Line 39: | Line 38: | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | |||
[[Category:Drugs FDA approved in 2014]] | [[Category:Drugs FDA approved in 2014]] | ||
| + | [[Category:PMDA approved drugs]] | ||
Revision as of 02:18, 9 August 2017
General information
Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ramucirumab (Cyramza) patient drug information (Chemocare)[4]
- Ramucirumab (Cyramza) package insert[1]
- Ramucirumab (Cyramza) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 4/21/2014: FDA approved "for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum- containing chemotherapy."
- 11/5/2014: FDA approval and indication expanded "for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma."
- 12/12/2014: FDA approved "for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy."
- 4/24/2015: FDA approved "in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine."
Also known as
IMC-1121B, LY3009806